Expert Interviews

Migraine Therapeutics Research that Made News with Neurologists in 2024: Interview with Peter McAllister, MD
January 08, 2025

Significant strides were made in 2024 in evaluating a wide range of treatments for migraine, including phase 2 findings with PACAP inhibition, PI McAllister said.

The Electrical Origins of Migraine May be Under the Microscope, Neurologist Peter McAllister, MD, Explains
January 07, 2025

The onset of migraine with its wide range of symptoms may be telegraphed as early as 2 days before by the frequency of neuronal oscillation deep in the brain.

Expert Perspectives 2024: Treatment for Agitation in Alzheimer Disease with George Grossberg, MD
January 03, 2025

Agitation affects at least one half of adults with Alzheimer disease; geriatric psychiatrist Grossberg explains the symptoms and new treatments in this year's video series.

Impact of OSA on Patient Health and Comorbidities
January 02, 2025

Panelists discuss how untreated obstructive sleep apnea (OSA) significantly increases patients’ risk of serious health complications, including cardiovascular disease, type 2 diabetes, depression, and cognitive impairment while exacerbating existing comorbidities.

For Alzheimer Agitation, a Novel, Oral NMDA Inhibitor Could be the Next Targeted Treatment
January 02, 2025

Geriatric psychiatrist and neurocognitive researcher George Grossberg, MD, highlights the mechanism of action for the new dextromethorphan/bupropion combination.

An Overview of Thyroid Cancer and Treatment Goals
December 24, 2024

Todd W. Frieze, MD, discusses the therapeutic role of TSH suppression in differentiated thyroid cancer, as well as treatment goals and ongoing surveillance strategies.

An Overview of Hypothyroidism
December 24, 2024

Alex Tessnow, MD, reviews the presentation of hypothyroidism among elderly patients and outlines key considerations for treatment.

Impact of Delayed Intervention In Stage 2 Type 1 Diabetes
December 23, 2024

Panelists discuss how delaying intervention during Stage 2 Type 1 diabetes increases the risk of diabetic ketoacidosis and complications at diagnosis, while also potentially accelerating beta cell destruction and reducing the window for preservation therapies.

Defining the Stages of Type 1 Diabetes
December 23, 2024

Panelists discuss how Type 1 diabetes progresses through distinct stages, from initial autoimmunity with normal blood glucose (Stage 1), to dysglycemia without symptoms (Stage 2), to clinical diagnosis with symptoms (Stage 3), marking critical intervention points for treatment and management.

Guidelines for Type 1 Diabetes Screening
December 23, 2024

Panelists discuss how screening for Type 1 diabetes should focus on identifying high-risk individuals through family history, genetic markers, and autoantibody testing, while emphasizing the importance of early detection to prevent diabetic ketoacidosis at diagnosis.